Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Jan 7, 2022

ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment

Jan 6, 2022

ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

Dec 16, 2021

ProMIS Neurosciences Issues Chairman’s Memorandum

Dec 2, 2021

ProMIS Neurosciences Shareholders Approve Special Resolution

Nov 17, 2021

A Second Independent Proxy Advisor, ISS, Recommends ProMIS Neurosciences Shareholders Vote for the Share Consolidation

Nov 12, 2021

ProMIS Neurosciences Announces Third Quarter 2021 Results

Nov 2, 2021

Glass Lewis Recommends ProMIS Neurosciences Shareholders Vote for the Share Consolidation at the Upcoming Special Meeting

Oct 22, 2021

ProMIS Neurosciences Announces Update to Senior Management Team

Oct 22, 2021

ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors

Oct 21, 2021

ProMIS Neurosciences Files Special Meeting Proxy Material

  • arrow_back
  • 1…
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …25
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy